News - Tysabri

Filter

Current filters:

Tysabri

Popular Filters

Elan board agrees $8.6 billion takeover bid

29-07-2013

US health care company Perrigo (NYSE: PRGO) revealed this morning that Ireland-based drugmaker Elan Corp…

ElanGenericsMergers & AcquisitionsPerrigoPharmaceuticalTysabri

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch

25-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Elan posts financials, as it explores sale of the company

25-07-2013

Ireland-based Elan Corp (NYSE:ELN) today reported its second quarter 2013 financial results, showing…

ElanFinancialMergers & AcquisitionsPharmaceuticalTysabri

Royalty Pharma hikes offer for Elan to $13 a share, plus CVR of up to $2.50

10-06-2013

Ireland-based Elan Corp (NYSE: ELN) saw its shares to 5.3% to $13.35 by mid morning last Friday (June…

ElanMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer

30-05-2013

In the ongoing saga of Royalty Pharma's takeover attempts, Ireland-based Elan (NYSE: ELN) has communicated…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan reports 1st-qtr operating loss

24-04-2013

Ireland-based Elan Corp (NYSE: ELN), which has again rejected takeover approach form Royalty Pharma and…

ElanFinancialPharmaceuticalTysabri

Elan to unlock benefits for shareholders from Tysabri deal

05-03-2013

The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan plans $1 billion repurchase program post Tysabri deal closure

22-02-2013

Ireland-headquartered drugmaker Elan Corp (NYSE: ELN) disclosed its deployment plans for the $3.25 billion…

ElanFinancialPharmaceuticalTysabri

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

New analysis of risk stratification for Biogen and Elan's Tysabri

20-05-2012

US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

Elan back in the black, boosted by Tysabri

09-02-2012

Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…

BiotechnologyElanFinancialTysabri

FDA updates Tysabri label relating to anti-JCV

23-01-2012

The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates

19-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

EU clears anti-JC virus risk labeling for Biogen and Elan’s Tysabri

23-06-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan (NYSE: ELN) said yesterday that the…

Biogen IdecBiotechnologyElanEuropeNeurologicalRegulationTysabri

Biogen Idec shares leap, as 1st-qtr 2011 earnings rocket, boosted by Tysabri; and by MS drug results

26-04-2011

Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) soared 20% to $104.11 in pre-market trading last…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTysabri

Back to top